文献速递认知障碍与痴呆

去铁酮治疗阿尔茨海默病:一项随机临床试验

Deferiprone in Alzheimer Disease: A Randomized Clinical Trial.
PubMed 文献 · JAMA Neurol · 2025-01-01

这项在澳大利亚9个中心开展的2期双盲安慰剂对照试验纳入81例淀粉样蛋白确诊的早期阿尔茨海默病患者,随机2:1接受去铁酮15 mg/kg每日两次或安慰剂治疗12个月。去铁酮组认知综合评分下降更快(β交互=-0.50),海马铁含量降低但海马体积丢失未受影响,中性粒细胞减少发生率高于同类研究。

要点

  • 去铁酮组NTB认知综合z评分变化-0.80,安慰剂组-0.30,交互β=-0.50(95%CI -0.80至-0.20)。
  • 去铁酮降低海马QSM(-0.36 ppb),安慰剂组为0.32 ppb,交互β=-0.68(95%CI -1.27至-0.09)。
  • 去铁酮组中性粒细胞减少4例(7.5%),高于同类研究的1.6%-4.4%。

核心结论

  • 去铁酮15 mg/kg每日两次降低海马QSM并加速淀粉样蛋白确诊早期AD患者的认知下降,提示降低铁对AD患者有害。

研究设计与样本

  • 2期、双盲、安慰剂对照随机临床试验,为期12个月,在澳大利亚9个中心于2018年8月2日至2023年4月1日开展。
  • 筛查167例,纳入81例,随机2:1分组:去铁酮组53例(平均[SD]年龄73.0[8.0]岁;男性29例[54.7%]),安慰剂组28例(平均[SD]年龄71.6[7.2]岁;男性17例[60.7%])。
  • 纳入标准为年龄大于54岁、淀粉样蛋白确诊的轻度认知障碍或早期AD(简易精神状态检查评分20分或以上)。
  • 干预为口服去铁酮15 mg/kg每日两次或安慰剂,持续12个月。
  • 主要结局为基线、6个月和12个月评估的记忆、执行功能和注意力神经心理测验组合(NTB)综合认知指标。

主要发现

  • 意向性治疗分析中,去铁酮组NTB主要结局认知下降加速(交互β=-0.50;95%CI -0.80至-0.20)。
  • NTB综合z评分变化:去铁酮组-0.80(95%CI -0.98至-0.62),安慰剂组-0.30(95%CI -0.54至-0.06)。
  • 次要分析显示该结果由执行功能测验表现恶化驱动。
  • QSM证实去铁酮较安慰剂降低海马铁:海马QSM变化去铁酮组-0.36 ppb(95%CI -0.76至0.04 ppb),安慰剂组0.32 ppb(95%CI -0.12至0.75 ppb),交互β=-0.68(95%CI -1.27至-0.09)。
  • 纵向海马体积丢失未受去铁酮影响,但其他脑区的探索性分析显示去铁酮组额叶区域体积丢失增加。

临床怎么用

  • 原文结论认为使用去铁酮降低铁对AD患者有害,未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Interventions that substantially slow neurodegeneration are needed to address the growing burden of Alzheimer disease (AD) to societies worldwide. Elevated brain iron observed in AD has been associated with accelerated cognitive decline and may be a tractable drug target. OBJECTIVE: To investigate whether the brain-permeable iron chelator deferiprone slows cognitive decline in people with AD. DESIGN, SETTING, AND PARTICIPANTS: This phase 2, double-masked, placebo-controlled randomized clinical trial of 12-month duration was conducted at 9 sites in Australia between August 2, 2018, and April 1, 2023. Patients older than 54 years with amyloid-confirmed mild cognitive impairment or early AD (a Mini-Mental State Examination score of 20 or higher) were screened. Randomization was 2:1 and masked to participants and all study staff. INTERVENTIONS: Deferiprone 15 mg/kg twice a day or placebo administered orally for 12 months. MAIN OUTCOMES AND MEASURES: The primary outcome was a composite cognitive measure assessed at baseline, 6 months, and 12 months using a neuropsychological test battery (NTB) of memory, executive function, and attention tasks. Secondary outcomes included change in brain iron burden measured by quantitative susceptibility mapping (QSM) magnetic resonance imaging (target engagement), brain volume changes (secondary efficacy measure), and adverse events (safety analysis). RESULTS: Of 167 patients screened for eligibility, 81 were included, with 53 randomly assigned to the deferiprone group (mean [SD] age, 73.0 [8.0] years; 29 male [54.7%]) and 28 to the placebo group (mean [SD] age, 71.6 [7.2] years; 17 male [60.7%]); 54 participants completed the study (7 [25.0%] withdrew from the placebo group and 20 [37.7%] from the deferiprone group). In an intention-to-treat analysis, participants in the deferiprone group showed accelerated cognitive decline on the NTB primary outcome (β for interaction = -0.50; 95% CI, -0.80 to -0.20) compared with placebo (change in NTB composite z score for deferiprone, -0.80 [95% CI, -0.98 to -0.62]; for placebo, -0.30 [95% CI, -0.54 to -0.06]). Secondary analysis revealed that this result was driven by worsening performance on executive function tests. The QSM confirmed that deferiprone decreased iron in the hippocampus compared with placebo (change in hippocampal QSM for deferiprone, -0.36 ppb [95% CI, -0.76 to 0.04 ppb]; for placebo, 0.32 ppb [95% CI, -0.12 to 0.75 ppb]; β for interaction = -0.68 [95% CI, -1.27 to -0.09]). Longitudinal hippocampal volume loss was not affected by deferiprone, but exploratory analysis of other brain regions revealed increased volume loss with deferiprone in frontal areas. The frequency of the adverse effect of neutropenia (4 participants [7.5%] in the deferiprone group) was higher than in similar studies (1.6%-4.4%). CONCLUSIONS: These trial findings show that deferiprone 15 mg/kg twice a day decreased hippocampal QSM and accelerated cognitive decline in patients with amyloid-confirmed early AD, suggesting that lowering iron with deferiprone is detrimental to patients with AD. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03234686.

来源:JAMA Neurol,查看原文。版权归原作者所有。

引用

  1. Ayton S, Barton D, Brew B, et al. Deferiprone in Alzheimer Disease: A Randomized Clinical Trial. JAMA Neurol. 2025. PMID: 39495531. doi:10.1001/jamaneurol.2024.3733

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。